Suppression of IgE antibody response against ovalbumin by the chemical conjugate of ovalbumin with a polyaspartic acid derivative.
Ovalbumin was modified with alpha,beta-poly[(2-hydroxyethyl)-DL-aspartamide] which had been developed as a nontoxic plasma expander. Preadministration of the modified ovalbumin suppressed both primary and secondary anti-ovalbumin IgE responses.